<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72279">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02010242</url>
  </required_header>
  <id_info>
    <org_study_id>GSN000200</org_study_id>
    <nct_id>NCT02010242</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genkyotex Innovation SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genkyotex Innovation SAS</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Poland: The Central Register of Clinical Trials</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic
      complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4
      inhibitor.

      The primary objective of this study is to evaluate the efficacy of oral GKT137831 in
      patients with residual albuminuria despite maximal inhibition of the renin angiotensin
      aldosterone system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled, randomized, multicenter, parallel group Phase 2 study
      assessing a 12-week period of treatment with oral GKT137831 administered in addition to
      standard of care for patients with type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>Visits 4 (week -2), 5 (week 0), 6 (week 2), 7 (week 4), 8 (week 6), 9 (week 8), 10 (week 10), 11 (week 12), and 12 (week 16)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in UACR from baseline to Visits 9, 10, and 11 (i.e. weeks 8, 10 and 12 of the treatment period, respectively)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>Visits 5 (week 0), 8 (week 6), and 11 (week 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in HOMA-B, HOMA-IR and HbA1c from baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Erectile dysfunction</measure>
    <time_frame>Visits 5 (week 0), 8 (week 6), and 11 (week 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in IEFF questionnaire assessing erectile dysfunction in patients presenting with these diabetic complications at baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuropathic pain</measure>
    <time_frame>Visits 5 (week 0), 8 (week 6), and 11 (week 12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in Visual Analog Scale (VAS) assessing neuropathic leg pain in patients presenting with these diabetic complications at baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes Mellitus With Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>GKT137831</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GKT137831 100 mg capsules twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GKT137831</intervention_name>
    <description>1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment</description>
    <arm_group_label>GKT137831</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female aged 18 to 80 years

          -  History of type 2 diabetes, defined as fasting plasma glucose ≥7.0 mmol/L (126 mg/dL)
             or a glycated hemoglobin (HbA1c) &gt;6.5% (48 mmol/mol) on at least 2 occasions prior to
             screening.

          -  Albuminuria defined as a UACR of 300 to 3500 mg/g.

          -  An eGFR ≥30 mL/min/1.73 m2, as calculated by the CKD-EPI formula.

          -  Must be taking an ACEI or an ARB for at least 6 weeks prior to the first screening
             visit (Visit 1) and during the screening period.  The dose must have been stable for
             at least 4 weeks prior to the first screening visit (Visit 1).  Combination therapy
             associating an ACEI and an ARB is not permitted.

        Key Exclusion Criteria:

          -  History of type 1 diabetes

          -  Any other non-diabetic kidney disease(s) except for hypertensive nephropathy which is
             acceptable.

          -  Diagnostic or interventional procedure requiring a contrast agent within 4 weeks of
             the first screening visit (Visit 1) or planned during the study.

          -  History of renal transplant or planned renal transplant during the study.

          -  A history of acute renal dialysis or acute kidney injury (defined according to the
             Kidney Disease: Improving Global Outcomes [KDIGO] definition) within 12 weeks of the
             first screening visit (Visit 1)

          -  HbA1c level &gt;11% (97 mmol/mol).

          -  History of hypothyroidism requiring hormone replacement therapy.

          -  History of active cardiovascular disease

          -  A personal or family history of long QT syndrome.

          -  Administration of any investigational product within 30 days or within 5 half-lives
             of the investigational agent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Wiesel, MD</last_name>
    <phone>+33.6.73.63.67.21</phone>
    <email>philippe.wiesel@genkyotex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacques Herve, MSc</last_name>
    <phone>+33.4.56.44.81.12</phone>
    <email>jacques.herve@genkyotex.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Richard Cherlin, MD</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Eves</last_name>
      <email>cherlinsoffice@msn.com</email>
    </contact>
    <investigator>
      <last_name>Richard Cherlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Endocrine Medical Group, Inc</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Bernabe</last_name>
      <email>emgresearch@aol.com</email>
    </contact>
    <investigator>
      <last_name>Samuel Mayeda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Cianferra</last_name>
      <email>eduardo@crsouthflorida.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Diabetes and Endocrine Care</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie-Ann Sylvia</last_name>
      <email>casilvia@bellsouth.net</email>
    </contact>
    <investigator>
      <last_name>Sam Lerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coral Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yania Lugo-Perez</last_name>
      <email>igf0503@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Edel Abreu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Castano</last_name>
      <email>pcricastano@aol.com</email>
    </contact>
    <investigator>
      <last_name>Steven Zeig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Volunteer Medical Research</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Ramos</last_name>
      <email>amelia.ramos.vmr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kianoosh Kaveh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John H. Stroger Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jadwiga Miernik</last_name>
      <email>jcm124@cchil.org</email>
    </contact>
    <investigator>
      <last_name>Leon Fogelfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Creighton Diabetes Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merideth Dunnwall</last_name>
      <email>Dunnwall@creighton.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Rendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harold Hamm Diabetes Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey Bixler</last_name>
      <email>lacey-bixler@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>James Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Salvatore</last_name>
      <email>Amanda.Salvatore@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Serge Jabbour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Nephrology &amp; Hypertension Center</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Jeffcoat</last_name>
      <email>renee@scnephrology.net</email>
    </contact>
    <investigator>
      <last_name>Moustafa Moustafa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Research</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Bohringer</last_name>
      <email>liz@renalresearch.com.au</email>
    </contact>
    <investigator>
      <last_name>Simon Roger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marrondah ECRU</name>
      <address>
        <city>East Ringwood</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerrie Peacock</last_name>
      <email>kerrie.peacock@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Murray Gertsman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Scanbellone</last_name>
      <email>sgr@unimelb.edu</email>
    </contact>
    <investigator>
      <last_name>Joe Proietto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baker Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lawton</last_name>
      <email>maria.lawton@bakeridi.edu.au</email>
    </contact>
    <investigator>
      <last_name>Anne Reutens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Captain Stirling Medical Centre</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Benson</last_name>
      <email>donnabenson@iinet.net.au</email>
    </contact>
    <investigator>
      <last_name>Michael Benson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keogh Institute for Medical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Anna Wagner</last_name>
      <email>JoAnna@kimr.org</email>
    </contact>
    <investigator>
      <last_name>Bronwin Stuckey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine Research Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6E1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Haydin</last_name>
      <email>jaydin.ers@shaw.ca</email>
    </contact>
    <investigator>
      <last_name>Hugh Tildesley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Endocrinology</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eden Stein</last_name>
      <email>eden.stein@lmc.ca</email>
    </contact>
    <investigator>
      <last_name>Hani Alasaad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Endocrinology</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eden Stein</last_name>
      <email>eden.stein@lmc.ca</email>
    </contact>
    <investigator>
      <last_name>Harpreet Bajaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 1J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Myrna Marticorena</last_name>
      <email>RosaMyrna.Marticorena@williamoslerhs.ca</email>
    </contact>
    <investigator>
      <last_name>Sandra Donnelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2H 5Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Mc Coy</last_name>
      <email>mccoy@cyg.net</email>
    </contact>
    <investigator>
      <last_name>Shivinder Jolly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OTT Healthcare</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1H3G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dione Rochester</last_name>
      <email>pywtam@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paul Tam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes and Endocrinology</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J8L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanvi Talsania</last_name>
      <email>Tanvi.talsania@lmc.ca</email>
    </contact>
    <investigator>
      <last_name>Ronald Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Endocrinololgy</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eden Stein</last_name>
      <email>eden.stein@lmc.ca</email>
    </contact>
    <investigator>
      <last_name>Ronnie Aronson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medpharmgene</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1Y 3L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Renee Guertin</last_name>
      <email>marie.renee.guertin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pavel Hamet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Milan Kvapil s.r.o. diabetology ambulance</name>
      <address>
        <city>Prague</city>
        <zip>14900</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Kreckova</last_name>
      <email>gabcica@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Dagmar Bartakovska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DiaGolfova s.r.o.</name>
      <address>
        <city>Prague</city>
        <zip>10000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Sutnerova</last_name>
      <email>danaburdova@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Dana Burdova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Znojmo</name>
      <address>
        <city>Znojmo</city>
        <zip>66902</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Najmonova</last_name>
      <email>ivana.najmonova@nemzn.cz</email>
    </contact>
    <investigator>
      <last_name>Danica Puskeilerova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Haematologie/Onkologie/Diabeteologie</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Steitenberger</last_name>
      <email>gk@klausmann.de</email>
    </contact>
    <investigator>
      <last_name>Gerhard Klausmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin GbR</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrein Dreykluft</last_name>
      <email>k.dreykluft@klinische-forschung-berlin.de</email>
    </contact>
    <investigator>
      <last_name>Isabelle Schenkenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Facharzt fur Allgemeinmedizin</name>
      <address>
        <city>Mannheim</city>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sina Schedler</last_name>
      <email>Sina.Schedler@t-online.de</email>
    </contact>
    <investigator>
      <last_name>Jurgen Wachter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IDFM</name>
      <address>
        <city>Munchen</city>
        <zip>48155</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Schroer</last_name>
      <email>a.schroer@diabetes-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Ludger Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Badaa Klinicznych PI-House Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bogdan Gajewski</last_name>
      <email>bogdan@pihouse.pl</email>
    </contact>
    <investigator>
      <last_name>Monica Lukaszewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Sp. z o.o. S.K.A. Oddzial w Gdyni</name>
      <address>
        <city>Gdynia</city>
        <zip>81338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Zarcycka</last_name>
      <email>jzarzycka@medicapf.pl</email>
    </contact>
    <investigator>
      <last_name>Anita Tarnowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Sp.zo.o S.K.A</name>
      <address>
        <city>Katowice</city>
        <zip>40954</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzina Papiernik</last_name>
      <email>kpapiernik@medicapf.pl</email>
    </contact>
    <investigator>
      <last_name>Ilona Cebula-Byrska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LANDA Specjalistyczne Gabinety Lekarskie</name>
      <address>
        <city>Krakow</city>
        <zip>30-015</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justina Stanek</last_name>
      <email>j.piestrzonek@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lidia Todarska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praktyka Lekarska Ewa Krzyzagorska</name>
      <address>
        <city>Poznan</city>
        <zip>61-655</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Krzyzagorska</last_name>
      <email>ewa.krzyzagorska@cs.pu.poznan.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Krzyzagorska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Sp. z o.o.</name>
      <address>
        <city>Staszow</city>
        <zip>28200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Ciepielewska</last_name>
      <email>marek.konieczny@ko-med.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Konieczny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Sp. z o.o. S.K.A.</name>
      <address>
        <city>Warsaw</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Furman</last_name>
      <email>pfurman@medicapf.pl</email>
    </contact>
    <investigator>
      <last_name>Agnieska Jurek-Urbanowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Albuminuria</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
